skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Drug development is challenging at the best of times, and made even harder within the realm of rare diseases. Overall, the largest number of drugs has targeted indications within the therapeutic areas of oncology and infectious disease (ID), with malaria being an area of high interest with both therapeutic and preventive interventions.

 

Read our full in depth analysis below to get the most accurate and timely intelligence about rare diseases drug development.

 

 

 

Find out more about Pharmaprojects here

Read also

  • Pharmaprojects: track pharma R&D

    Find the right investigators and sites for your clinical trial using granular, real-world data.

    Gain vital insight into study feasibility, site selection, and investigator prioritization with granular data from the new Informa Pharma Intelligence Patient Proximity API. Protect yourself against costly trial delays by using it to choose the right investigators with relevant and sizable patient proximity. 

    Topics Clinical Trial Optimization Clinical Trials

  • Biomedtracker: see the drug development process through anal...

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topics Coronavirus

  • Pharmaprojects: track pharma R&D

    Pharma RD Annual Review 2020 Whitepaper

    By Ian Lloyd

    Using the new, granular datapoints in Pharmaprojects, Senior Director Ian Lloyd presents his expert insights into pharma’s R&D activities over the past year and what they may mean for the pipeline during the year to come. The 27th instalment of the Annual Review, this version takes advantage of improvements to Pharmaprojects’ data granularity to bring you details on pharma R&D trends

    Topics Drug Development Landscape Drug Review Research & Development

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

After submitting your details, you will have access to all content resources available on this website
Tems and Conditions
Additional Fields

Informa Privacy Policy    Informa Terms & Conditions